Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT
Phase 1
Recruiting
- Conditions
- Immune reconstitution post-allogeneic haematopoietic stem cell transplantationOther - Other blood disorders
- Registration Number
- ACTRN12605000213640
- Lead Sponsor
- Department of Haematology, Westmead Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
HLA-A*0201 pos and CMV seropositive donor, 5/6 or 6/6 sib match or 6/6/MUD, GVHD < grade II at the time of infusion, >day 28 post allogeneic HSCT, no recent anti-lymphocyte globulin.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of donor-derived CMV-specific CTL infusion post-transplant[];Feasibility of donor-derived CMV-specific CTL infusion post-transplant[]
- Secondary Outcome Measures
Name Time Method Persistence/reconstitution of CMV-specific CTL.[]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HLA-A*0201-restricted CMV pp65 peptide-specific CTL activity in immune reconstitution post-allogeneic HSCT?
How does donor-derived CMV-specific CTL infusion compare to antiviral prophylaxis in preventing CMV reactivation post-allogeneic HSCT?
Which biomarkers, including HLA-A*0201 expression, predict successful immune reconstitution with CMV-specific CTL infusion after allogeneic HSCT?
What are the potential adverse events and management strategies in ACTRN12605000213640's donor-derived CMV-specific CTL infusion post-allogeneic HSCT?
What combination therapies with donor-derived CMV-specific CTL are being explored to enhance immune reconstitution post-allogeneic HSCT?